Sai Life Sciences unveils 2024–25 sustainability report

The company also reported significant progress toward its internally defined Sustainable Development Goals

Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder

The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1

Biocon’s S&P Global ESG Score improves to 69 for 2024

Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53

Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024

Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance

Warren Remedies commences commercial production of APIs

Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health

Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency

Piramal Pharma appoints Vibha Paul Rishi as Non- Executive Director

Essential Pharma progress in its ESG performance

The company now exceeds the sector benchmark for its overall ESG rating and for all three measures

India's bio-economy has grown 8 times in the last 8 years: PM Modi

We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”

India’s pharma exports grow by 103% since 2013-14

Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions